SCHEMBL6637549

SCHEMBL6637549

C[C@H](N)Cc1ccc(Cl)s1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 5/20 0.45
SLC6A3 Q01959 4/20 0.45
PNMT P11086 2/20 0.41
TAAR1 Q96RJ0 6/20 0.39
SLC6A4 P31645 3/20 0.39
MAOA P21397 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
CYP2A6 P11509 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP19A1 P11511 1/20 0.37
HTR2A P28223 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6638096 1.00 SLC6A2 (0.45) SLC6A2SLC6A3PNMTTAAR1SLC6A4
SCHEMBL27286918 1.00 SLC6A2 (0.45) SLC6A2SLC6A3PNMTTAAR1SLC6A4
SCHEMBL8250906 0.83 ALDH1A1 (0.42) SLC6A2SLC6A3SLC6A4ALDH1A1HTT
SCHEMBL7721243 0.80 HTR2A (0.40) SLC6A2SLC6A3SLC6A4ALDH1A1HTT
SCHEMBL25362839 0.79 KMT2A (0.42) SLC6A2SLC6A3SLC6A4ALDH1A1HTT
SCHEMBL9071088 0.79 KMT2A (0.42) SLC6A2SLC6A3SLC6A4ALDH1A1HTT
SCHEMBL6682061 0.79 KMT2A (0.42) SLC6A2SLC6A3SLC6A4ALDH1A1HTT
SCHEMBL6638065 0.77 TAAR1 (0.40) SLC6A2SLC6A3TAAR1SLC6A4MAOA
SCHEMBL3460972 0.77 TAAR1 (0.40) SLC6A2SLC6A3TAAR1SLC6A4MAOA
SCHEMBL6636274 0.77 PRMT6 (0.47) SLC6A2SLC6A3TAAR1SLC6A4MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0758897-B1 COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES AVENTIS PHARM PROD INC (US) 2004-02-25 EP disclosed
US-6392049-B1 NITRATION USING NITRIC ACID AVENTIS PHARMACEUTICALS INC. 2002-05-21 US disclosed
US-6307054-B1 HEATING A 5-CARBOXY-2,4-DIHYROXYPYRIDINE AND PHOSPHORIC ACID WHERE THE RATIO OF PHOSPHORIC ACID TO WATER IS NOT LESS THAN ABOUT 27 TO 1 WEIGHT %. AVENTIS PHARMACEUTICALS PRODUCTS INC. 2001-10-23 US disclosed
EP-1006115-A2 Imidazopyridines having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 2000-06-07 EP disclosed
EP-0909270-A4 1999-04-21 EP disclosed
EP-0909270-A1 PROCESS FOR PREPARING 2,4-DIHYDROXYPYRIDINE AND 2,4-DIHYDROXY-3-NITROPYRIDINE RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1999-04-21 EP disclosed
US-5736554-A TREATING AND/OR PREVENTING CARDIOVASCULAR DISORDERS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1998-04-07 US disclosed
EP-0758897-A4 COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES RHONE POULENC RORER PHARMA (US) 1997-11-19 EP disclosed
US-5652366-A ADENOSINE AGONISTS; HYPOTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC, AND ANTILIPOLYTIC AGENTS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1997-07-29 US disclosed
WO-1997024327-A1 PROCESS FOR PREPARING 2,4-DIHYDROXYPYRIDINE AND 2,4-DIHYDROXY-3-NITROPYRIDINE RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1997-07-10 WO disclosed
EP-0758897-A1 COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1997-02-26 EP disclosed
US-5561134-A ADENOSINE DERIVATIVES RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1996-10-01 US disclosed
WO-1995028160-A1 COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1995-10-26 WO disclosed
US-5364862-A Adenosine derivatives RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1994-11-15 US disclosed